{"ticker": {"uuid": "695f9286-3234-49b9-aa33-78a97b4691c6", "symbol": "PRME", "name": "Prime Medicine, Inc. Common Stock", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Prime Medicine (PRME) Reaches Positive Resolution to Arbitration with Beam Therapeutics", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/prime-medicine-prme-reaches-positive-085317803.html", "source_name": "Insider Monkey", "published_at": "2026-07-15T08:53:17+00:00", "published_display": "15 Jul 2026 08:53", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sumitomo Mitsui Trust Group Inc. Has $10.23 Million Stock Position in Prime Medicine, Inc. $PRME", "summary": "Sumitomo Mitsui Trust Group Inc. reduced its stake in Prime Medicine (NASDAQ:PRME) by 9.4% in the first quarter, now holding 2.94 million shares valued at $10.23 million. Despite this reduction, institutional ownership remains high at 70.37%, with other major institutional invest", "url": "https://www.marketbeat.com/instant-alerts/filing-sumitomo-mitsui-trust-group-inc-has-1023-million-stock-position-in-prime-medicine-inc-prme-2026-07-15/", "source_name": "MarketBeat", "published_at": "2026-07-15T08:51:28", "published_display": "15 Jul 2026 08:51", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Prime Medicine Inc. (PRME) Stock Price | Live Quotes & Charts | NASDAQ", "summary": "", "url": "https://news.google.com/rss/articles/CBMiUkFVX3lxTE5weEVjU011Y3IxNUw3WDBWaEltek92OWtJOWZzZmFqM1RQNW0yUU9wcVNHbEpUaVVfNVVMUEFPeDhsX2pUc2VSUTAydDFKc3cyVVE?oc=5", "source_name": "timothysykes.com", "published_at": "2026-07-14T19:48:41+00:00", "published_display": "14 Jul 2026 19:48", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Prime Medicine (NASDAQ:PRME) Shares Down 6.5% - Should You Sell?", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxPaUJHd2k4U0pqNzJ3Vnk0MkJ0YWxIOExrbmpmQ19oblFDZVU4Mm5ycG5iQVRCYlFrY1EzZ0k1bG4tR0NBVmFSd3d4NjJ5NVdsajVjbFMzTm5BalBTSThnU0Q4VEJ3bGJydFN3ZVVlMklUbXFFVHVBUmZSaG1oUjVjRHhjd1BheFliT2oxanlQaVF4LTlqa2hSU0w1UmM3QVd6YjV6clBncGtzNkhfYTRn?oc=5", "source_name": "MarketBeat", "published_at": "2026-07-13T17:07:43+00:00", "published_display": "13 Jul 2026 17:07", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Prime Medicine Stock Dips As Traders Weigh Heavy Losses", "summary": "Prime Medicine Inc. (PRME) stock has dipped by 9.69% due to negative sentiment surrounding its latest pipeline developments and significant financial losses despite minimal revenue. The company is characterized as a high-risk, early-stage gene-editing platform with a limited cash", "url": "https://timothysykes.com/news/primemedicineinc-prme-news-2026_07_11/", "source_name": "timothysykes.com", "published_at": "2026-07-11T15:11:41", "published_display": "11 Jul 2026 15:11", "sentiment": "negative", "sentiment_pct": 8, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Prime Medicine, Inc. \u2013 NASDAQ:PRME", "summary": "This article provides financial information for Prime Medicine, Inc. (NASDAQ: PRME), specifically its enterprise value to EBITDA forward. It notes that the market is currently closed with no trades. The article is primarily a data point page from TradingView, focusing on key fina", "url": "https://www.tradingview.com/symbols/NASDAQ-PRME/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-07-11T10:10:05", "published_display": "11 Jul 2026 10:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Prime Medicine gains after winning arbitration with Beam Therapeutics", "summary": "Prime Medicine's stock rose in after-hours trading following a favorable decision in its arbitration with Beam Therapeutics. The arbitration ruling confirmed that Prime Medicine holds exclusive rights to certain foundational intellectual property for its PRIME editing technology.", "url": "https://www.msn.com/en-us/health/medical/prime-medicine-gains-after-winning-arbitration-with-beam-therapeutics/ar-AA27tVBn", "source_name": "MSN", "published_at": "2026-07-11T08:10:05", "published_display": "11 Jul 2026 08:10", "sentiment": "positive", "sentiment_pct": 86, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Prime Medicine Down Nearly 14%, on Pace for Largest Percent Decrease Since May 2025 -- Data Talk", "summary": "Prime Medicine (PRME) stock is experiencing a significant decline, currently down nearly 14%. This puts the company on track for its largest percentage decrease since May 2025. The article highlights this notable drop in stock performance for Prime Medicine.", "url": "https://www.moomoo.com/news/post/72791734/prime-medicine-down-nearly-14-on-pace-for-largest-percent?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-07-10T20:39:46", "published_display": "10 Jul 2026 20:39", "sentiment": "negative", "sentiment_pct": 20, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PRME Stock Slides As Traders Weigh Heavy Losses And Cash Runway", "summary": "Prime Medicine Inc. (PRME) stock is down over 10% as traders react to its heavy losses and uncertain cash runway despite an earlier rally. While the company boasts high gross margins and some liquidity with $135.5M in cash, it faces significant quarterly net losses and R&D spendi", "url": "https://stockstotrade.com/news/prime-medicine-inc-prme-news-2026_07_10/", "source_name": "StocksToTrade", "published_at": "2026-07-10T17:41:37", "published_display": "10 Jul 2026 17:41", "sentiment": "negative", "sentiment_pct": 29, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cathie Wood Dumps AMD, Doubles Down on Meta Stock", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/cathie-wood-dumps-amd-doubles-125714691.html", "source_name": "GuruFocus.com", "published_at": "2026-07-10T12:57:14+00:00", "published_display": "10 Jul 2026 12:57", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright reiterates Prime Medicine stock rating at buy", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxNVjM2UnNpOFJUU1ItMmdrc2FSbklFWnpEN0VXN3gwa2lGdXJRWnVVdURFQW9yRVBqTkJhUDFGaVZyS1dwaGpGbTBrNk01UGtKcTZUZnd6UmpidTFfd2VCMkFIcGhuNUx1bWY1cVhYYW5Ma3lnTkFNRml0bndNMFZ5VkVfbGF0RDVnTTk1NFlwWXJ3dVNDWXdtMXYtb2VSdFhpZDczUUlkYjZlM3pqVXZjajE3V1NFY0VtZ3BR?oc=5", "source_name": "Investing.com", "published_at": "2026-07-10T12:17:02+00:00", "published_display": "10 Jul 2026 12:17", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Prime Medicine(PRME) Stock Options Chain | Quotes & News", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0AJBVV95cUxNVnFwWkNJZXgxdXZ6Zy1hWC1tSGM3bC1yYlZWUjJKY2p3cGUxZElsR19YYzFMcXlweG54UktURmhGb1lnRmlZVU5PblQyS2hpT1k3Wkk1TDlaaU9hbFdLaHcwZGRaajhQQ2R5MnM1SWxFQ0ZJaFR4bzJGLXFzVWVsWi1IelZxNHZ4dWpCZXY3a1hWS3pMc2dVSldyaG84RzAtRzZWQS03R2lXQ0JkRVB3WFZRbmJjZjM3UUxzeVBfNmtZZDZ5V0xtVWN4aE85S05PTTRaWkdoZ3Z6Q0xxZHY1bTVjRXdnc1BMN3c5aTZicXVLMHdNYlVFUkpqNW41WUVEM29yS3d1SG0xeDFHX28tZThEaUcwUEF0clpjUUw2WkVYRHJpbmtoUUMxX3lMLUVneHFLTUVsdTZhZFNTRE8tQk5jcFktVHZxTS1tdFdTdjc?oc=5", "source_name": "Moomoo", "published_at": "2026-07-09T19:38:57+00:00", "published_display": "09 Jul 2026 19:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Prime Medicine Beats Beam Therapeutics In Patent Dispute - But Both Are Investable (PRME)", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxOYmI4LVQ4TDh1OHVLMDdnLTFMTXpPb0dIQ0VNR29GdmlSbFh3bE5VclphaTNrVDVDcDN5WUFFeGJqWFpjM3BwcE9Xb2hLcElUb1Q5aENReEZPVmZpZlJtLXdJVHZUVUFENVRSMnAwYVppdWJBRTF5Slo4dUt1SXpWNTdmVURFbjBId2NzLU41UVdEd1NITkEzVzdBS3lXZVJnQ05ud1p1WEV5LS05dDJpQWIzZEhyR2lLc3VTcnl3?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-07-09T14:22:58+00:00", "published_display": "09 Jul 2026 14:22", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Prime Medicine Wins AATD Gene Therapy Arbitration", "summary": "Prime Medicine has won an arbitration against Beam Therapeutics, confirming its exclusive development rights for PM647, a prime editing therapy for alpha-1 antitrypsin deficiency (AATD). This decision clears PM647 for clinical entry, with an IND/CTA filing targeted for Q3 2026 an", "url": "https://allsci.com/news/patents-ip/prime-medicine-prevails-in-beam-dispute-retaining-exclusive-rights-to-aatd-therapy-pm647/", "source_name": "AllSci", "published_at": "2026-07-09T12:39:46", "published_display": "09 Jul 2026 12:39", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Prime Medicine Shares Rise on Positive Arbitration Ruling in Beam Dispute", "summary": "Prime Medicine's shares saw a significant increase following an arbitration panel's ruling in its favor against Beam Therapeutics, upholding the validity of certain intellectual property licensed exclusively to Prime Medicine. The decision confirms the validity of foundational pa", "url": "https://www.moomoo.com/news/post/72660519/prime-medicine-shares-rise-on-positive-arbitration-ruling-in-beam", "source_name": "Moomoo", "published_at": "2026-07-09T08:11:41", "published_display": "09 Jul 2026 08:11", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Prime Medicine, Inc. (NASDAQ:PRME) Given Consensus Recommendation of \"Moderate Buy\" by Analysts", "summary": "Analysts have given Prime Medicine, Inc. (NASDAQ:PRME) a consensus \"Moderate Buy\" rating, with an average 12-month price target of $7.53. The stock rose 15.8% recently, trading at $4.62, below its 52-week high of $6.94. The company reported a wider-than-expected quarterly loss of", "url": "https://www.marketbeat.com/instant-alerts/prime-medicine-inc-nasdaqprme-given-consensus-recommendation-of-moderate-buy-by-analysts-2026-07-09/", "source_name": "MarketBeat", "published_at": "2026-07-09T08:11:41", "published_display": "09 Jul 2026 08:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Prime Medicine claims victory in dispute over gene-editing technology with Beam Therapeutics", "summary": "Prime Medicine has won an arbitration dispute against Beam Therapeutics regarding gene-editing technology for alpha-1 antitrypsin deficiency (AATD). The ruling allows Prime to proceed with clinical trials for AATD and is a setback for Beam, which called the decision disagreed wit", "url": "https://www.bostonglobe.com/2026/07/08/business/prime-medicine-gene-editing-beam-therapeutics/", "source_name": "The Boston Globe", "published_at": "2026-07-08T21:09:55", "published_display": "08 Jul 2026 21:09", "sentiment": "positive", "sentiment_pct": 75, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Update: Prime Medicine Receives Favorable Ruling in Beam Therapeutics License Arbitration; Shares Rise", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/prime-medicine-receives-favorable-ruling-180823492.html", "source_name": "MT Newswires", "published_at": "2026-07-08T18:08:23+00:00", "published_display": "08 Jul 2026 18:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TD Cowen reiterates Buy on Prime Medicine stock after arbitration win", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxNeTRnbnU4aFNlcmNTX3ZhQVZnU1YyV0pWSklHZEdyN0Z5bi00RjF6UG9uT015cl9oTHJHRXdfRUZFWHlCT3lZRzJCZFNHSHhELUJOYi05bk1tMXZyZng3b2xVMHpIMXBNdlctU3k0TW5tVm1pM3MzZFp5TGlyT0JnUlJqXzBiSmRGYjJTYVNBQ09sVVZ5Q3NHX2lzWm82alpNNWRwWGJVRG5FZzVfTnZqY3VGYzlyd1FvdmticWVnYmtlbjJlby12VA?oc=5", "source_name": "Investing.com", "published_at": "2026-07-08T17:39:49+00:00", "published_display": "08 Jul 2026 17:39", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Prime Medicine wins binding arbitration against Beam Therapeutics", "summary": "", "url": "https://news.google.com/rss/articles/CBMikgFBVV95cUxQNjBsR1lQal9qWUJ0V09jeXpGekluM3RvRzdjVkJ4Y2JHbG9DRDF3bHdVTkdGMDZaUG9fcFh4Vk9mYUVMWFItaHRwUVJNRnloeGJJcXQzUHBjS1hVbGY2UG1nQW1odTZLOVlLMEFlNHNWQTRWWTlQRjkweHcxUnI5eDFzNUp4a0FlUm1wRW9xLXhDdw?oc=5", "source_name": "grafa.com", "published_at": "2026-07-08T16:26:00+00:00", "published_display": "08 Jul 2026 16:26", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Prime Medicine Receives Favorable Ruling in Beam Therapeutics License Arbitration", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/prime-medicine-receives-favorable-ruling-160256429.html", "source_name": "MT Newswires", "published_at": "2026-07-08T16:02:56+00:00", "published_display": "08 Jul 2026 16:02", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Prime Medicine stock surges after winning arbitration with Beam", "summary": "Prime Medicine Inc. (NASDAQ: PRME) shares rose significantly after the company won a binding arbitration ruling against Beam Therapeutics Inc. (NASDAQ: BEAM). The ruling confirms Prime Medicine's development rights to PM647, an investigational treatment for Alpha-1 Antitrypsin De", "url": "https://www.investing.com/news/stock-market-news/prime-medicine-stock-surges-after-winning-arbitration-with-beam-93CH-4781966", "source_name": "Investing.com", "published_at": "2026-07-08T14:41:33", "published_display": "08 Jul 2026 14:41", "sentiment": "positive", "sentiment_pct": 86, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Prime wins patent fight with Beam to continue work on AATD gene editing therapy", "summary": "Prime Medicine has won a patent dispute against Beam Therapeutics, allowing it to continue developing its lead gene-editing therapy, PM647, for alpha-1 antitrypsin deficiency (AATD). The arbitration tribunal ruled that Prime did not violate its 2019 agreement with Beam and does n", "url": "https://www.fiercebiotech.com/biotech/prime-wins-patent-fight-beam-can-continue-work-aatd-gene-editing-therapy", "source_name": "Fierce Biotech", "published_at": "2026-07-08T14:40:09", "published_display": "08 Jul 2026 14:40", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Prime Medicine resolves arbitration, clarifying PM647 development rights", "summary": "Prime Medicine, Inc. announced that an arbitration tribunal ruled in its favor regarding its PM647 development candidate, affirming it falls within Prime's agreed field and dismissing Beam Therapeutics' claims. This resolution clarifies Prime Medicine's development rights and rem", "url": "https://www.tipranks.com/news/company-announcements/prime-medicine-resolves-arbitration-clarifying-pm647-development-rights", "source_name": "TipRanks", "published_at": "2026-07-08T12:41:33", "published_display": "08 Jul 2026 12:41", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Prime Medicine wins arbitration over AATD therapy PM647", "summary": "Prime Medicine Inc. (NASDAQ:PRME) has won an arbitration against Beam Therapeutics Inc. concerning its investigational therapy PM647 for Alpha-1 Antitrypsin Deficiency, confirming the drug falls within Prime Medicine\u2019s licensed field and no monetary damages are owed. This ruling ", "url": "https://www.investing.com/news/company-news/prime-medicine-wins-arbitration-over-aatd-therapy-pm647-93CH-4781487", "source_name": "Investing.com", "published_at": "2026-07-08T12:40:09", "published_display": "08 Jul 2026 12:40", "sentiment": "positive", "sentiment_pct": 82, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Prime Medicine clears Beam dispute, keeps PM647 for AATD", "summary": "Prime Medicine (Nasdaq: PRME) announced a binding arbitration win against Beam Therapeutics, confirming its right to develop and commercialize PM647 for Alpha-1 Antitrypsin Deficiency (AATD) and owing no damages to Beam. PM647 leverages Prime Editing to correct a prevalent mutati", "url": "https://www.stocktitan.net/news/PRME/prime-medicine-announces-positive-resolution-to-arbitration-with-mlbmhidaegzp.html", "source_name": "Stock Titan", "published_at": "2026-07-08T11:40:09", "published_display": "08 Jul 2026 11:40", "sentiment": "positive", "sentiment_pct": 91, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Prime Medicine Announces Positive Resolution to Arbitration with Beam Therapeutics", "summary": "Prime Medicine announced a positive resolution to its arbitration with Beam Therapeutics, confirming its right to develop and commercialize PM647 for Alpha-1 Antitrypsin Deficiency (AATD) and owing no monetary damages. The company plans to submit an IND/CTA filing for PM647 in Q3", "url": "https://www.globenewswire.com/news-release/2026/07/08/3324031/0/en/prime-medicine-announces-positive-resolution-to-arbitration-with-beam-therapeutics.html", "source_name": "GlobeNewswire", "published_at": "2026-07-08T11:40:09", "published_display": "08 Jul 2026 11:40", "sentiment": "positive", "sentiment_pct": 91, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Prime wins gene editing dispute; Saol claims latest post-Makary FDA reversal", "summary": "", "url": "https://finance.yahoo.com/m/9d6b70fc-12d8-3018-b625-3ca13b9fa945/prime-wins-gene-editing.html", "source_name": "BioPharma Dive", "published_at": "2026-07-08T09:07:00+00:00", "published_display": "08 Jul 2026 09:07", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Prime Medicine Stock Pops As ARK, Analysts Back Gene Editor", "summary": "Prime Medicine (PRME) stock surged by 15.91% due to significant gene-editing advancements and strong institutional backing. The company received FDA RMAT designation for its PM359 program and clearance from New Zealand for its PM577a trial, marking its first in vivo Prime Editing", "url": "https://stockstotrade.com/news/prime-medicine-inc-prme-news-2026_07_08/", "source_name": "StocksToTrade", "published_at": "2026-07-08T10:03:00", "published_display": "08 Jul 2026 10:03", "sentiment": "positive", "sentiment_pct": 91, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "10 Overlooked Penny Stocks to Buy Right Now", "summary": "This article highlights Prime Medicine, Inc. (NASDAQ: PRME) as an overlooked penny stock with significant upside potential. The company recently received regulatory clearances for its gene-editing therapies, including acceptance of a clinical trial application for PM577a in New Z", "url": "https://www.insidermonkey.com/blog/10-overlooked-penny-stocks-to-buy-right-now-1795387/4/", "source_name": "Insider Monkey", "published_at": "2026-07-05T00:10:07", "published_display": "05 Jul 2026 00:10", "sentiment": "positive", "sentiment_pct": 71, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PRME - Prime Medicine Inc Options", "summary": "This article provides a detailed financial overview of Prime Medicine Inc (PRME), including its last close price of $3.87, key valuation metrics like market cap and enterprise value, and various financial ratios. It also highlights performance indicators, analyst recommendations,", "url": "https://finviz.com/stock?t=PRME&ty=oc&ta=1&p=w&ov=chain_date&e=2026-06-18", "source_name": "Finviz", "published_at": "2026-07-03T05:40:42", "published_display": "03 Jul 2026 05:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Prime Medicine, Inc. \u2013 NASDAQ:PRME", "summary": "This article provides a brief mention of Prime Medicine, Inc. (NASDAQ:PRME) and its enterprise value to revenue forward metric. The content appears to be a stub or a section within a larger financial data platform, indicating the availability of financial information for the comp", "url": "https://www.tradingview.com/symbols/NASDAQ-PRME/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-30T18:43:21", "published_display": "30 Jun 2026 18:43", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Prime Medicine, Inc. \u2013 NASDAQ:PRME", "summary": "This article briefly highlights the \"Price to book forward\" metric for Prime Medicine, Inc., traded under the NASDAQ:PRME symbol. It appears to be a financial data point from a larger platform, likely TradingView, indicating specific financial information for the company. The con", "url": "https://www.tradingview.com/symbols/NASDAQ-PRME/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-30T04:01:57", "published_display": "30 Jun 2026 04:01", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright upgrades Prime Medicine stock rating to buy", "summary": "H.C. Wainwright has upgraded Prime Medicine (NASDAQ:PRME) from Neutral to Buy, setting an $8.00 price target after New Zealand approved the Clinical Trial Application for PM577a, an investigational therapy for Wilson\u2019s Disease. This clearance marks the first clinical authorizatio", "url": "https://www.investing.com/news/analyst-ratings/hc-wainwright-upgrades-prime-medicine-stock-rating-to-buy-93CH-4765072", "source_name": "Investing.com", "published_at": "2026-06-29T11:41:42", "published_display": "29 Jun 2026 11:41", "sentiment": "positive", "sentiment_pct": 74, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amazon Stock Climbs During Strong Day For Magnificent Seven", "summary": "", "url": "https://news.google.com/rss/articles/CBMikgFBVV95cUxPS0d1N0FldnNuR2xlNEFqMWd1MnRLcDY3eElfOWV5VEJJSjJhTThJalJUWjBrbFcwYVY0TnBlTldYc1JiajNUb21TYXFPVVg1MW9vVnpSZTNQdnVNbDVRcVl3aFBkc1BJbnYybE1EeThKR0NpajhxaVBkZzRaVEQ4ZGFzNkIycEN1UXJXa1E5OFg3UQ?oc=5", "source_name": "Investor's Business Daily", "published_at": "2026-06-29T07:00:00+00:00", "published_display": "29 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "New Analyst Forecast: $PRME Given $8 Price Target | PRME Stock News", "summary": "", "url": "https://news.google.com/rss/articles/CBMikgFBVV95cUxNdGtTN2JqNzU4UTRHb0V0U0lKOVhSR3Awc3V4UWpPcWtWX2FQSFdGblNadE9IenFUTFAwd0pucy1ScDFkemZMeU83WHRmb0Z1aW1aWUxEd25SOUM5OExnNjM3QnZSRHBZMU0zal9sc2NnTTNmdVdoUk1CTFM3ZkRPZ2VpYWlfanVMbF9RU3U1Nk5JZw?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-06-29T07:00:00+00:00", "published_display": "29 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amazon Boosted By Prime Day Data, Unveils Robotaxi Updates. Stock Climbs.", "summary": "", "url": "https://news.google.com/rss/articles/CBMijAFBVV95cUxOOVZyRFMtbDI2MTVUeVNUME1WTjJpek5CS3VZaFJGdG9JMGZ0UVM2U3huU2dzd2NkT2U5MS1qeTlSTjZFV1ExQnBUUHlOOUhoVUZ2SVRhalMwbzlsWWNJbGxkLXFBc1NKRzUyZHNMT1BsMTliUDVobEc3MW5nRi1Ea2MzVzRqeHRiMU44Qw?oc=5", "source_name": "Investor's Business Daily", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LifeSci Capital Maintains Prime Medicine(PRME.US) With Buy Rating, Maintains Target Price $6", "summary": "LifeSci Capital has reiterated its Buy rating for Prime Medicine (PRME.US) and maintained a target price of $6. The firm's analysis supports a positive outlook for the company.", "url": "https://www.moomoo.com/news/post/71891910/lifesci-capital-maintains-prime-medicine-prmeus-with-buy-rating-maintains", "source_name": "Moomoo", "published_at": "2026-06-24T02:10:18", "published_display": "24 Jun 2026 02:10", "sentiment": "positive", "sentiment_pct": 77, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Prime Medicine Says PM359 Granted US FDA Regenerative Medicine Advanced Therapy Designation", "summary": "Prime Medicine announced that the FDA has granted Regenerative Medicine Advanced Therapy (RMAT) designation to PM359. PM359 is an investigational Prime Editor designed to correct the genetic cause of chronic granulomatous disease (CGD). The company previously received Orphan Drug", "url": "https://www.moomoo.com/news/post/71829787/prime-medicine-says-pm359-granted-us-fda-regenerative-medicine-advanced", "source_name": "Moomoo", "published_at": "2026-06-22T12:40:42", "published_display": "22 Jun 2026 12:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Prime Medicine\u2019s CGD therapy gets FDA RMAT, speeding review", "summary": "Prime Medicine (PRME) has been granted Regenerative Medicine Advanced Therapy (RMAT) designation by the FDA for its investigational therapy PM359, aimed at treating p47phox-deficient chronic granulomatous disease (CGD). This designation, supported by positive Phase 1/2 clinical d", "url": "https://www.stocktitan.net/news/PRME/prime-medicine-receives-u-s-fda-regenerative-medicine-advanced-49g2uj0ysq0y.html", "source_name": "Stock Titan", "published_at": "2026-06-22T11:59:50", "published_display": "22 Jun 2026 11:59", "sentiment": "positive", "sentiment_pct": 85, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Prime Medicine Receives U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for PM359 for the Treatment of Chronic Granulomatous Disease (CGD)", "summary": "Prime Medicine, Inc. announced that the U.S. FDA has granted Regenerative Medicine Advanced Therapy (RMAT) designation to PM359 for the treatment of p47 phox -deficient chronic granulomatous disease (CGD). This designation is based on promising Phase 1/2 clinical data, including ", "url": "https://www.globenewswire.com/news-release/2026/06/22/3315247/0/en/Prime-Medicine-Receives-U-S-FDA-Regenerative-Medicine-Advanced-Therapy-RMAT-Designation-for-PM359-for-the-Treatment-of-Chronic-Granulomatous-Disease-CGD.html", "source_name": "GlobeNewswire", "published_at": "2026-06-22T11:59:50", "published_display": "22 Jun 2026 11:59", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Citizens reiterates Prime Medicine stock rating on gene therapy focus", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxObTREVzV2R1JEb2lGQVJja0hpaE0xMzZkdnJRd2hSRnowb3REMFc4am8tYUlLUjdGZTkwTHFRQmtXVHQ0SDJ6SzBld0FJM1BjdFN6MG03OTU0b3lDV1NqZi1iM0RZTkp2X1k0Z2pjYXVzWVNuWkJ0bVhzSDN3Znl1TzVnTUdGSEhFZmZsa3FQcTVzV2d3TFg5RDNJYnppd1V4anJtRGt0b1FhRWhuWU5Qb2l0SS1BTDc3czhCWjBpMWdsaWxGNUJWbw?oc=5", "source_name": "Investing.com", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Analysts Are Bullish on These Healthcare Stocks: Prime Medicine, Inc. (PRME), Ocular Therapeutix (OCUL)", "summary": "LifeSci Capital analyst Cory Jubinville maintained a Buy rating on Prime Medicine, Inc. (PRME) with a $6.00 price target. Needham analyst Serge Belanger also maintained a Buy rating on Ocular Therapeutix (OCUL) with an $18.00 price target, aligning with a Strong Buy consensus for", "url": "https://www.theglobeandmail.com/investing/markets/stocks/OCUL/pressreleases/2559926/analysts-are-bullish-on-these-healthcare-stocks-prime-medicine-inc-prme-ocular-therapeutix-ocul/", "source_name": "The Globe and Mail", "published_at": "2026-06-20T00:09:09", "published_display": "20 Jun 2026 00:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology Stock Rises 19% in 3 Months: Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxQM0ExNm9zZVBVMzB2cTFsYkhQeDJyeUV5Y1lSdWdsa2V2STFTSFBkYVlrRDJaUmE0bjZVLUxmZEh1UkFPbndtdWVDWmJBcEJaSmpTSlN4RkFkdF9EYkhFUXh3YWxqREkxRllfRXE0bFVuSkMwaExFNmk0UmNoa2R2NmQyb0p1N2pudENMMGMwWmVGT0J5SUxfeE5hT2hpUms1NHR4NzY1VWpNQVFYUWJkUnN3?oc=5", "source_name": "TradingView", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "We're Keeping An Eye On Prime Medicine's (NASDAQ:PRME) Cash Burn Rate", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxNMWRXUTNpcHZJVnN4OXlvaXlOUGplVTRuRUFfdGppaXp4ZUk4LUZhMVRfMnFnbGtlbm02QWw4TDFqLVlTX0xPa3ZFUnpoTEstTUVtUU04NE5ZYWNwVjdkTUR3WldyUDk0dlk5eVRlSHdvT09LZ2Uta3V1X3hyTF90RTBXbElqV0JZUHdrTnpJeUc4MGdoM2Q4ZmtPak9mZw?oc=5", "source_name": "Market source", "published_at": "2026-06-04T07:00:00+00:00", "published_display": "04 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UNH stock jumps on Q1 earnings beat and raised guidance to $18.25+", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxPTEprdzNMNGZxdkg5Wll5MTlvS1dheXQybm14TERTcGVzcHQzY0llOEpTa0dpZ1hGdHVyNWZ2cFFiWmZRdkl1aUp4YVlTMVJxSDRzaEdzRFB1cW93QzdhSmNxcEZDMWhGX2F0ODJFcjY1Mk1kMVhLNnVJSUhVMHZpRjRtTHo2cXBvbVJ3a05SWlJNMUdrSzFPbA?oc=5", "source_name": "eciks.org", "published_at": "2026-05-26T07:00:00+00:00", "published_display": "26 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 84, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Prime Medicine (PRME) Reports Q1 EPS", "summary": "", "url": "https://news.google.com/rss/articles/CBMiggFBVV95cUxQZnBPRUh0ZXc3U3p6RzZ2SmpqM2xLZC1BY3o3cTd4N3BLcEQ3OTl4QkJRTVhZaml2OXdyd2tRMkRGY3FERTRVYjktUFdLZUtueUQySmI4NU9GOUpVWGllMXJxQV93VE1FMDBreVNDTnpOLVlETEc2MXhBLUJoZWJMQzl3?oc=5", "source_name": "Market source", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PDS BIOTECHNOLOGY ($PDSB) Releases Q1 2026 Earnings | PDSB Stock News", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxOcEdqLWM1SmVuNHpvZ2poNU5mOFppaWNtUi1IQVRHTmgxLUpyZHdUSDRnekdzMmVFQzFzUGo2RjlYenpCaTlfcUZhMm1yTzRwWUxnM01WY0libmxIVXNSM3RtMGxMY2RURTdMVW96bGU0SGZXRkE2SnVQdVNNUWw5RWtJQVJMX2pQQnRBRHBKMlRCUDct?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxOWWM3V1pmZzdlY1llRTljQmNLQ2UwdDdQaFVEcng2WVdrNE9qNzRrNVpBVlJNMGltQUhBUG1qellCVHNiM09fUkFHRW1kMEpvazJoLU11N3c4YnlWUXpmVl82aWNKeTA4U1RwSHNNSVd4d0lwWHRJclQ2TGNHWUpBQTgzbTBMVk05VGxYN0RwcmpTYklOQUFSWDhsSHZlQVpndmlPRGNvTmRmeHNILWg4ZE5jMjRoN01XNENiaVU2UDUyOWJfYUZCTm5URmtwTHJsTjJYNHo3RkxsQjBSMnBmdVZVWkFwN2PSAewBQVVfeXFMT3htM016bEt0TTdyOXE2amppMGpubTNfOFU4cGpxd2dFZkJDTjR3c0ZqOHpHYWZoamNLdmkxVmNYNklxTEM4NTU0bDZwUTZ1SW5Jc1c4NmRJN3lKQUVqUUNYYWptd2ZYNE9TeEhMRzFvbEt0bjk1TVhyVG44UnJnNDllTlFsalJVUTZwcEEzWXljbzdaQXdWWDlHQW56bGxqeG90UlFmaFFLekJlUlNIOVE4SGNHcE9pOW1KSllleVdwNERiaVl2NmxtNTNyaUtnSFY1VHUzcDJsWE9xb3R1ajZ2RGhkXzJzTldMOVA?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Prime Medicine (Nasdaq: PRME) Q1 2026 results, cash runway into 2027 and pipeline update", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxQd1RCY25tNUFfdkF3SU1mMVlMamMtTkxVQmFPME82S2J1V2hrczZUYXVDSGQ0ZGdPdXpnQWtDVFFYZkxBMU1tRWt5cDdlbjFVaWx1WlZLcjdZWkxUUk5YdEs0YW9SUlN6Qnp1cU1mUHZ0elRhWGxRVEc2VU13TjhzRW41NGRQY0NKVkRPdzZaWDE1eEJudEZzVFZGLXNWOFVIVjNNS2JBcGw3UTQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GE HealthCare (NASDAQ:GEHC) Posts Better-Than-Expected Sales In Q1 CY2026 But Stock Drops", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3gFBVV95cUxOUjRRb0hlcHlOazlmelFaVVJSQWNnRmExZVBEQW1HMmVLTjNyU3d4WElsU05hdGlfYWFSY0twMTNWOVVCY0h4U2dYQ19BQl9pa3o0NWNBLW50WmFsSEVHdmJFV3JabnN5MFZpUWZabjZzY2tjMUtxbndONm9DS3NxTUp3Qjg2dWZnMDR2NXZ2eU80MWhSODVKdVgxZVJ6TWs3RFpCaDFqMXVtVkhmRVlOcWtqYUV1X1FPcGpfdERhRmwzdkZDaWxtSnJnd25Oam4yTnFHTFBkZi0tM1BZdkE?oc=5", "source_name": "StockStory", "published_at": "2026-04-29T07:00:00+00:00", "published_display": "29 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Abbott is the most oversold healthcare stock as Q1 earnings roll on (XLV:NYSEARCA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxOc2thQjFpazgwaFRfS3NjVXhlTkdFWHNFb240S0Z6akFtQXFIMmFmaXZnQ1A3OFVCQW9DT25OLVBQdGN5Yk52Mk9yUFlSX19ZS3FRTjZoR05zc2FVc25pVHQ0TDVHT2JmVnJabGNCREdLT2stV0IzLVdHWXpFZGU3V1NnVGhYbFRzNURVek41TVRmLWZQZTFYUkc4aXM0a1cwTkNFYTBfVnQ?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-04-22T07:00:00+00:00", "published_display": "22 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "CFO package at Prime Medicine (NASDAQ: PRME) details pay, options and severance", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxPb1hTSVozUW1hQVZQeElHUHBCR2tnTXNpUkZVSEdQZFNudmRCd0VJX2NUUHhSZU9tN2dFaUhiWXJzOXVwYkk2RDhFb1R0SWdrSWhrb2VVbWpmbXNOaF9jbng1OWhqVFNJTVdKd2hSRTRkSWNjTXRDS0lRQl9LZ21mSy1WZzdmMGtzdVF5MFZmMEFwYW9FeDI3M0RtSnNBRWNnTWVick5VOWsxZjg?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-16T07:00:00+00:00", "published_display": "16 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "by_tier": {"direct": [{"title": "Prime Medicine (PRME) Reaches Positive Resolution to Arbitration with Beam Therapeutics", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/prime-medicine-prme-reaches-positive-085317803.html", "source_name": "Insider Monkey", "published_at": "2026-07-15T08:53:17+00:00", "published_display": "15 Jul 2026 08:53", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sumitomo Mitsui Trust Group Inc. Has $10.23 Million Stock Position in Prime Medicine, Inc. $PRME", "summary": "Sumitomo Mitsui Trust Group Inc. reduced its stake in Prime Medicine (NASDAQ:PRME) by 9.4% in the first quarter, now holding 2.94 million shares valued at $10.23 million. Despite this reduction, institutional ownership remains high at 70.37%, with other major institutional invest", "url": "https://www.marketbeat.com/instant-alerts/filing-sumitomo-mitsui-trust-group-inc-has-1023-million-stock-position-in-prime-medicine-inc-prme-2026-07-15/", "source_name": "MarketBeat", "published_at": "2026-07-15T08:51:28", "published_display": "15 Jul 2026 08:51", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Prime Medicine Inc. (PRME) Stock Price | Live Quotes & Charts | NASDAQ", "summary": "", "url": "https://news.google.com/rss/articles/CBMiUkFVX3lxTE5weEVjU011Y3IxNUw3WDBWaEltek92OWtJOWZzZmFqM1RQNW0yUU9wcVNHbEpUaVVfNVVMUEFPeDhsX2pUc2VSUTAydDFKc3cyVVE?oc=5", "source_name": "timothysykes.com", "published_at": "2026-07-14T19:48:41+00:00", "published_display": "14 Jul 2026 19:48", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Prime Medicine (NASDAQ:PRME) Shares Down 6.5% - Should You Sell?", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxPaUJHd2k4U0pqNzJ3Vnk0MkJ0YWxIOExrbmpmQ19oblFDZVU4Mm5ycG5iQVRCYlFrY1EzZ0k1bG4tR0NBVmFSd3d4NjJ5NVdsajVjbFMzTm5BalBTSThnU0Q4VEJ3bGJydFN3ZVVlMklUbXFFVHVBUmZSaG1oUjVjRHhjd1BheFliT2oxanlQaVF4LTlqa2hSU0w1UmM3QVd6YjV6clBncGtzNkhfYTRn?oc=5", "source_name": "MarketBeat", "published_at": "2026-07-13T17:07:43+00:00", "published_display": "13 Jul 2026 17:07", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Prime Medicine Stock Dips As Traders Weigh Heavy Losses", "summary": "Prime Medicine Inc. (PRME) stock has dipped by 9.69% due to negative sentiment surrounding its latest pipeline developments and significant financial losses despite minimal revenue. The company is characterized as a high-risk, early-stage gene-editing platform with a limited cash", "url": "https://timothysykes.com/news/primemedicineinc-prme-news-2026_07_11/", "source_name": "timothysykes.com", "published_at": "2026-07-11T15:11:41", "published_display": "11 Jul 2026 15:11", "sentiment": "negative", "sentiment_pct": 8, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Prime Medicine, Inc. \u2013 NASDAQ:PRME", "summary": "This article provides financial information for Prime Medicine, Inc. (NASDAQ: PRME), specifically its enterprise value to EBITDA forward. It notes that the market is currently closed with no trades. The article is primarily a data point page from TradingView, focusing on key fina", "url": "https://www.tradingview.com/symbols/NASDAQ-PRME/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-07-11T10:10:05", "published_display": "11 Jul 2026 10:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Prime Medicine gains after winning arbitration with Beam Therapeutics", "summary": "Prime Medicine's stock rose in after-hours trading following a favorable decision in its arbitration with Beam Therapeutics. The arbitration ruling confirmed that Prime Medicine holds exclusive rights to certain foundational intellectual property for its PRIME editing technology.", "url": "https://www.msn.com/en-us/health/medical/prime-medicine-gains-after-winning-arbitration-with-beam-therapeutics/ar-AA27tVBn", "source_name": "MSN", "published_at": "2026-07-11T08:10:05", "published_display": "11 Jul 2026 08:10", "sentiment": "positive", "sentiment_pct": 86, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Prime Medicine Down Nearly 14%, on Pace for Largest Percent Decrease Since May 2025 -- Data Talk", "summary": "Prime Medicine (PRME) stock is experiencing a significant decline, currently down nearly 14%. This puts the company on track for its largest percentage decrease since May 2025. The article highlights this notable drop in stock performance for Prime Medicine.", "url": "https://www.moomoo.com/news/post/72791734/prime-medicine-down-nearly-14-on-pace-for-largest-percent?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-07-10T20:39:46", "published_display": "10 Jul 2026 20:39", "sentiment": "negative", "sentiment_pct": 20, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PRME Stock Slides As Traders Weigh Heavy Losses And Cash Runway", "summary": "Prime Medicine Inc. (PRME) stock is down over 10% as traders react to its heavy losses and uncertain cash runway despite an earlier rally. While the company boasts high gross margins and some liquidity with $135.5M in cash, it faces significant quarterly net losses and R&D spendi", "url": "https://stockstotrade.com/news/prime-medicine-inc-prme-news-2026_07_10/", "source_name": "StocksToTrade", "published_at": "2026-07-10T17:41:37", "published_display": "10 Jul 2026 17:41", "sentiment": "negative", "sentiment_pct": 29, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cathie Wood Dumps AMD, Doubles Down on Meta Stock", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/cathie-wood-dumps-amd-doubles-125714691.html", "source_name": "GuruFocus.com", "published_at": "2026-07-10T12:57:14+00:00", "published_display": "10 Jul 2026 12:57", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright reiterates Prime Medicine stock rating at buy", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxNVjM2UnNpOFJUU1ItMmdrc2FSbklFWnpEN0VXN3gwa2lGdXJRWnVVdURFQW9yRVBqTkJhUDFGaVZyS1dwaGpGbTBrNk01UGtKcTZUZnd6UmpidTFfd2VCMkFIcGhuNUx1bWY1cVhYYW5Ma3lnTkFNRml0bndNMFZ5VkVfbGF0RDVnTTk1NFlwWXJ3dVNDWXdtMXYtb2VSdFhpZDczUUlkYjZlM3pqVXZjajE3V1NFY0VtZ3BR?oc=5", "source_name": "Investing.com", "published_at": "2026-07-10T12:17:02+00:00", "published_display": "10 Jul 2026 12:17", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Prime Medicine(PRME) Stock Options Chain | Quotes & News", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0AJBVV95cUxNVnFwWkNJZXgxdXZ6Zy1hWC1tSGM3bC1yYlZWUjJKY2p3cGUxZElsR19YYzFMcXlweG54UktURmhGb1lnRmlZVU5PblQyS2hpT1k3Wkk1TDlaaU9hbFdLaHcwZGRaajhQQ2R5MnM1SWxFQ0ZJaFR4bzJGLXFzVWVsWi1IelZxNHZ4dWpCZXY3a1hWS3pMc2dVSldyaG84RzAtRzZWQS03R2lXQ0JkRVB3WFZRbmJjZjM3UUxzeVBfNmtZZDZ5V0xtVWN4aE85S05PTTRaWkdoZ3Z6Q0xxZHY1bTVjRXdnc1BMN3c5aTZicXVLMHdNYlVFUkpqNW41WUVEM29yS3d1SG0xeDFHX28tZThEaUcwUEF0clpjUUw2WkVYRHJpbmtoUUMxX3lMLUVneHFLTUVsdTZhZFNTRE8tQk5jcFktVHZxTS1tdFdTdjc?oc=5", "source_name": "Moomoo", "published_at": "2026-07-09T19:38:57+00:00", "published_display": "09 Jul 2026 19:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Prime Medicine Beats Beam Therapeutics In Patent Dispute - But Both Are Investable (PRME)", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxOYmI4LVQ4TDh1OHVLMDdnLTFMTXpPb0dIQ0VNR29GdmlSbFh3bE5VclphaTNrVDVDcDN5WUFFeGJqWFpjM3BwcE9Xb2hLcElUb1Q5aENReEZPVmZpZlJtLXdJVHZUVUFENVRSMnAwYVppdWJBRTF5Slo4dUt1SXpWNTdmVURFbjBId2NzLU41UVdEd1NITkEzVzdBS3lXZVJnQ05ud1p1WEV5LS05dDJpQWIzZEhyR2lLc3VTcnl3?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-07-09T14:22:58+00:00", "published_display": "09 Jul 2026 14:22", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Prime Medicine Wins AATD Gene Therapy Arbitration", "summary": "Prime Medicine has won an arbitration against Beam Therapeutics, confirming its exclusive development rights for PM647, a prime editing therapy for alpha-1 antitrypsin deficiency (AATD). This decision clears PM647 for clinical entry, with an IND/CTA filing targeted for Q3 2026 an", "url": "https://allsci.com/news/patents-ip/prime-medicine-prevails-in-beam-dispute-retaining-exclusive-rights-to-aatd-therapy-pm647/", "source_name": "AllSci", "published_at": "2026-07-09T12:39:46", "published_display": "09 Jul 2026 12:39", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Prime Medicine Shares Rise on Positive Arbitration Ruling in Beam Dispute", "summary": "Prime Medicine's shares saw a significant increase following an arbitration panel's ruling in its favor against Beam Therapeutics, upholding the validity of certain intellectual property licensed exclusively to Prime Medicine. The decision confirms the validity of foundational pa", "url": "https://www.moomoo.com/news/post/72660519/prime-medicine-shares-rise-on-positive-arbitration-ruling-in-beam", "source_name": "Moomoo", "published_at": "2026-07-09T08:11:41", "published_display": "09 Jul 2026 08:11", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Prime Medicine, Inc. (NASDAQ:PRME) Given Consensus Recommendation of \"Moderate Buy\" by Analysts", "summary": "Analysts have given Prime Medicine, Inc. (NASDAQ:PRME) a consensus \"Moderate Buy\" rating, with an average 12-month price target of $7.53. The stock rose 15.8% recently, trading at $4.62, below its 52-week high of $6.94. The company reported a wider-than-expected quarterly loss of", "url": "https://www.marketbeat.com/instant-alerts/prime-medicine-inc-nasdaqprme-given-consensus-recommendation-of-moderate-buy-by-analysts-2026-07-09/", "source_name": "MarketBeat", "published_at": "2026-07-09T08:11:41", "published_display": "09 Jul 2026 08:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Prime Medicine claims victory in dispute over gene-editing technology with Beam Therapeutics", "summary": "Prime Medicine has won an arbitration dispute against Beam Therapeutics regarding gene-editing technology for alpha-1 antitrypsin deficiency (AATD). The ruling allows Prime to proceed with clinical trials for AATD and is a setback for Beam, which called the decision disagreed wit", "url": "https://www.bostonglobe.com/2026/07/08/business/prime-medicine-gene-editing-beam-therapeutics/", "source_name": "The Boston Globe", "published_at": "2026-07-08T21:09:55", "published_display": "08 Jul 2026 21:09", "sentiment": "positive", "sentiment_pct": 75, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Update: Prime Medicine Receives Favorable Ruling in Beam Therapeutics License Arbitration; Shares Rise", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/prime-medicine-receives-favorable-ruling-180823492.html", "source_name": "MT Newswires", "published_at": "2026-07-08T18:08:23+00:00", "published_display": "08 Jul 2026 18:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TD Cowen reiterates Buy on Prime Medicine stock after arbitration win", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxNeTRnbnU4aFNlcmNTX3ZhQVZnU1YyV0pWSklHZEdyN0Z5bi00RjF6UG9uT015cl9oTHJHRXdfRUZFWHlCT3lZRzJCZFNHSHhELUJOYi05bk1tMXZyZng3b2xVMHpIMXBNdlctU3k0TW5tVm1pM3MzZFp5TGlyT0JnUlJqXzBiSmRGYjJTYVNBQ09sVVZ5Q3NHX2lzWm82alpNNWRwWGJVRG5FZzVfTnZqY3VGYzlyd1FvdmticWVnYmtlbjJlby12VA?oc=5", "source_name": "Investing.com", "published_at": "2026-07-08T17:39:49+00:00", "published_display": "08 Jul 2026 17:39", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Prime Medicine wins binding arbitration against Beam Therapeutics", "summary": "", "url": "https://news.google.com/rss/articles/CBMikgFBVV95cUxQNjBsR1lQal9qWUJ0V09jeXpGekluM3RvRzdjVkJ4Y2JHbG9DRDF3bHdVTkdGMDZaUG9fcFh4Vk9mYUVMWFItaHRwUVJNRnloeGJJcXQzUHBjS1hVbGY2UG1nQW1odTZLOVlLMEFlNHNWQTRWWTlQRjkweHcxUnI5eDFzNUp4a0FlUm1wRW9xLXhDdw?oc=5", "source_name": "grafa.com", "published_at": "2026-07-08T16:26:00+00:00", "published_display": "08 Jul 2026 16:26", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Prime Medicine Receives Favorable Ruling in Beam Therapeutics License Arbitration", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/prime-medicine-receives-favorable-ruling-160256429.html", "source_name": "MT Newswires", "published_at": "2026-07-08T16:02:56+00:00", "published_display": "08 Jul 2026 16:02", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Prime Medicine stock surges after winning arbitration with Beam", "summary": "Prime Medicine Inc. (NASDAQ: PRME) shares rose significantly after the company won a binding arbitration ruling against Beam Therapeutics Inc. (NASDAQ: BEAM). The ruling confirms Prime Medicine's development rights to PM647, an investigational treatment for Alpha-1 Antitrypsin De", "url": "https://www.investing.com/news/stock-market-news/prime-medicine-stock-surges-after-winning-arbitration-with-beam-93CH-4781966", "source_name": "Investing.com", "published_at": "2026-07-08T14:41:33", "published_display": "08 Jul 2026 14:41", "sentiment": "positive", "sentiment_pct": 86, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Prime wins patent fight with Beam to continue work on AATD gene editing therapy", "summary": "Prime Medicine has won a patent dispute against Beam Therapeutics, allowing it to continue developing its lead gene-editing therapy, PM647, for alpha-1 antitrypsin deficiency (AATD). The arbitration tribunal ruled that Prime did not violate its 2019 agreement with Beam and does n", "url": "https://www.fiercebiotech.com/biotech/prime-wins-patent-fight-beam-can-continue-work-aatd-gene-editing-therapy", "source_name": "Fierce Biotech", "published_at": "2026-07-08T14:40:09", "published_display": "08 Jul 2026 14:40", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Prime Medicine resolves arbitration, clarifying PM647 development rights", "summary": "Prime Medicine, Inc. announced that an arbitration tribunal ruled in its favor regarding its PM647 development candidate, affirming it falls within Prime's agreed field and dismissing Beam Therapeutics' claims. This resolution clarifies Prime Medicine's development rights and rem", "url": "https://www.tipranks.com/news/company-announcements/prime-medicine-resolves-arbitration-clarifying-pm647-development-rights", "source_name": "TipRanks", "published_at": "2026-07-08T12:41:33", "published_display": "08 Jul 2026 12:41", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Prime Medicine wins arbitration over AATD therapy PM647", "summary": "Prime Medicine Inc. (NASDAQ:PRME) has won an arbitration against Beam Therapeutics Inc. concerning its investigational therapy PM647 for Alpha-1 Antitrypsin Deficiency, confirming the drug falls within Prime Medicine\u2019s licensed field and no monetary damages are owed. This ruling ", "url": "https://www.investing.com/news/company-news/prime-medicine-wins-arbitration-over-aatd-therapy-pm647-93CH-4781487", "source_name": "Investing.com", "published_at": "2026-07-08T12:40:09", "published_display": "08 Jul 2026 12:40", "sentiment": "positive", "sentiment_pct": 82, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Prime Medicine clears Beam dispute, keeps PM647 for AATD", "summary": "Prime Medicine (Nasdaq: PRME) announced a binding arbitration win against Beam Therapeutics, confirming its right to develop and commercialize PM647 for Alpha-1 Antitrypsin Deficiency (AATD) and owing no damages to Beam. PM647 leverages Prime Editing to correct a prevalent mutati", "url": "https://www.stocktitan.net/news/PRME/prime-medicine-announces-positive-resolution-to-arbitration-with-mlbmhidaegzp.html", "source_name": "Stock Titan", "published_at": "2026-07-08T11:40:09", "published_display": "08 Jul 2026 11:40", "sentiment": "positive", "sentiment_pct": 91, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Prime Medicine Announces Positive Resolution to Arbitration with Beam Therapeutics", "summary": "Prime Medicine announced a positive resolution to its arbitration with Beam Therapeutics, confirming its right to develop and commercialize PM647 for Alpha-1 Antitrypsin Deficiency (AATD) and owing no monetary damages. The company plans to submit an IND/CTA filing for PM647 in Q3", "url": "https://www.globenewswire.com/news-release/2026/07/08/3324031/0/en/prime-medicine-announces-positive-resolution-to-arbitration-with-beam-therapeutics.html", "source_name": "GlobeNewswire", "published_at": "2026-07-08T11:40:09", "published_display": "08 Jul 2026 11:40", "sentiment": "positive", "sentiment_pct": 91, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Prime wins gene editing dispute; Saol claims latest post-Makary FDA reversal", "summary": "", "url": "https://finance.yahoo.com/m/9d6b70fc-12d8-3018-b625-3ca13b9fa945/prime-wins-gene-editing.html", "source_name": "BioPharma Dive", "published_at": "2026-07-08T09:07:00+00:00", "published_display": "08 Jul 2026 09:07", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Prime Medicine Stock Pops As ARK, Analysts Back Gene Editor", "summary": "Prime Medicine (PRME) stock surged by 15.91% due to significant gene-editing advancements and strong institutional backing. The company received FDA RMAT designation for its PM359 program and clearance from New Zealand for its PM577a trial, marking its first in vivo Prime Editing", "url": "https://stockstotrade.com/news/prime-medicine-inc-prme-news-2026_07_08/", "source_name": "StocksToTrade", "published_at": "2026-07-08T10:03:00", "published_display": "08 Jul 2026 10:03", "sentiment": "positive", "sentiment_pct": 91, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "10 Overlooked Penny Stocks to Buy Right Now", "summary": "This article highlights Prime Medicine, Inc. (NASDAQ: PRME) as an overlooked penny stock with significant upside potential. The company recently received regulatory clearances for its gene-editing therapies, including acceptance of a clinical trial application for PM577a in New Z", "url": "https://www.insidermonkey.com/blog/10-overlooked-penny-stocks-to-buy-right-now-1795387/4/", "source_name": "Insider Monkey", "published_at": "2026-07-05T00:10:07", "published_display": "05 Jul 2026 00:10", "sentiment": "positive", "sentiment_pct": 71, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PRME - Prime Medicine Inc Options", "summary": "This article provides a detailed financial overview of Prime Medicine Inc (PRME), including its last close price of $3.87, key valuation metrics like market cap and enterprise value, and various financial ratios. It also highlights performance indicators, analyst recommendations,", "url": "https://finviz.com/stock?t=PRME&ty=oc&ta=1&p=w&ov=chain_date&e=2026-06-18", "source_name": "Finviz", "published_at": "2026-07-03T05:40:42", "published_display": "03 Jul 2026 05:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Prime Medicine, Inc. \u2013 NASDAQ:PRME", "summary": "This article provides a brief mention of Prime Medicine, Inc. (NASDAQ:PRME) and its enterprise value to revenue forward metric. The content appears to be a stub or a section within a larger financial data platform, indicating the availability of financial information for the comp", "url": "https://www.tradingview.com/symbols/NASDAQ-PRME/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-30T18:43:21", "published_display": "30 Jun 2026 18:43", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Prime Medicine, Inc. \u2013 NASDAQ:PRME", "summary": "This article briefly highlights the \"Price to book forward\" metric for Prime Medicine, Inc., traded under the NASDAQ:PRME symbol. It appears to be a financial data point from a larger platform, likely TradingView, indicating specific financial information for the company. The con", "url": "https://www.tradingview.com/symbols/NASDAQ-PRME/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-30T04:01:57", "published_display": "30 Jun 2026 04:01", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright upgrades Prime Medicine stock rating to buy", "summary": "H.C. Wainwright has upgraded Prime Medicine (NASDAQ:PRME) from Neutral to Buy, setting an $8.00 price target after New Zealand approved the Clinical Trial Application for PM577a, an investigational therapy for Wilson\u2019s Disease. This clearance marks the first clinical authorizatio", "url": "https://www.investing.com/news/analyst-ratings/hc-wainwright-upgrades-prime-medicine-stock-rating-to-buy-93CH-4765072", "source_name": "Investing.com", "published_at": "2026-06-29T11:41:42", "published_display": "29 Jun 2026 11:41", "sentiment": "positive", "sentiment_pct": 74, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amazon Stock Climbs During Strong Day For Magnificent Seven", "summary": "", "url": "https://news.google.com/rss/articles/CBMikgFBVV95cUxPS0d1N0FldnNuR2xlNEFqMWd1MnRLcDY3eElfOWV5VEJJSjJhTThJalJUWjBrbFcwYVY0TnBlTldYc1JiajNUb21TYXFPVVg1MW9vVnpSZTNQdnVNbDVRcVl3aFBkc1BJbnYybE1EeThKR0NpajhxaVBkZzRaVEQ4ZGFzNkIycEN1UXJXa1E5OFg3UQ?oc=5", "source_name": "Investor's Business Daily", "published_at": "2026-06-29T07:00:00+00:00", "published_display": "29 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "New Analyst Forecast: $PRME Given $8 Price Target | PRME Stock News", "summary": "", "url": "https://news.google.com/rss/articles/CBMikgFBVV95cUxNdGtTN2JqNzU4UTRHb0V0U0lKOVhSR3Awc3V4UWpPcWtWX2FQSFdGblNadE9IenFUTFAwd0pucy1ScDFkemZMeU83WHRmb0Z1aW1aWUxEd25SOUM5OExnNjM3QnZSRHBZMU0zal9sc2NnTTNmdVdoUk1CTFM3ZkRPZ2VpYWlfanVMbF9RU3U1Nk5JZw?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-06-29T07:00:00+00:00", "published_display": "29 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amazon Boosted By Prime Day Data, Unveils Robotaxi Updates. Stock Climbs.", "summary": "", "url": "https://news.google.com/rss/articles/CBMijAFBVV95cUxOOVZyRFMtbDI2MTVUeVNUME1WTjJpek5CS3VZaFJGdG9JMGZ0UVM2U3huU2dzd2NkT2U5MS1qeTlSTjZFV1ExQnBUUHlOOUhoVUZ2SVRhalMwbzlsWWNJbGxkLXFBc1NKRzUyZHNMT1BsMTliUDVobEc3MW5nRi1Ea2MzVzRqeHRiMU44Qw?oc=5", "source_name": "Investor's Business Daily", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LifeSci Capital Maintains Prime Medicine(PRME.US) With Buy Rating, Maintains Target Price $6", "summary": "LifeSci Capital has reiterated its Buy rating for Prime Medicine (PRME.US) and maintained a target price of $6. The firm's analysis supports a positive outlook for the company.", "url": "https://www.moomoo.com/news/post/71891910/lifesci-capital-maintains-prime-medicine-prmeus-with-buy-rating-maintains", "source_name": "Moomoo", "published_at": "2026-06-24T02:10:18", "published_display": "24 Jun 2026 02:10", "sentiment": "positive", "sentiment_pct": 77, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Prime Medicine Says PM359 Granted US FDA Regenerative Medicine Advanced Therapy Designation", "summary": "Prime Medicine announced that the FDA has granted Regenerative Medicine Advanced Therapy (RMAT) designation to PM359. PM359 is an investigational Prime Editor designed to correct the genetic cause of chronic granulomatous disease (CGD). The company previously received Orphan Drug", "url": "https://www.moomoo.com/news/post/71829787/prime-medicine-says-pm359-granted-us-fda-regenerative-medicine-advanced", "source_name": "Moomoo", "published_at": "2026-06-22T12:40:42", "published_display": "22 Jun 2026 12:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Prime Medicine\u2019s CGD therapy gets FDA RMAT, speeding review", "summary": "Prime Medicine (PRME) has been granted Regenerative Medicine Advanced Therapy (RMAT) designation by the FDA for its investigational therapy PM359, aimed at treating p47phox-deficient chronic granulomatous disease (CGD). This designation, supported by positive Phase 1/2 clinical d", "url": "https://www.stocktitan.net/news/PRME/prime-medicine-receives-u-s-fda-regenerative-medicine-advanced-49g2uj0ysq0y.html", "source_name": "Stock Titan", "published_at": "2026-06-22T11:59:50", "published_display": "22 Jun 2026 11:59", "sentiment": "positive", "sentiment_pct": 85, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Prime Medicine Receives U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for PM359 for the Treatment of Chronic Granulomatous Disease (CGD)", "summary": "Prime Medicine, Inc. announced that the U.S. FDA has granted Regenerative Medicine Advanced Therapy (RMAT) designation to PM359 for the treatment of p47 phox -deficient chronic granulomatous disease (CGD). This designation is based on promising Phase 1/2 clinical data, including ", "url": "https://www.globenewswire.com/news-release/2026/06/22/3315247/0/en/Prime-Medicine-Receives-U-S-FDA-Regenerative-Medicine-Advanced-Therapy-RMAT-Designation-for-PM359-for-the-Treatment-of-Chronic-Granulomatous-Disease-CGD.html", "source_name": "GlobeNewswire", "published_at": "2026-06-22T11:59:50", "published_display": "22 Jun 2026 11:59", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Citizens reiterates Prime Medicine stock rating on gene therapy focus", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxObTREVzV2R1JEb2lGQVJja0hpaE0xMzZkdnJRd2hSRnowb3REMFc4am8tYUlLUjdGZTkwTHFRQmtXVHQ0SDJ6SzBld0FJM1BjdFN6MG03OTU0b3lDV1NqZi1iM0RZTkp2X1k0Z2pjYXVzWVNuWkJ0bVhzSDN3Znl1TzVnTUdGSEhFZmZsa3FQcTVzV2d3TFg5RDNJYnppd1V4anJtRGt0b1FhRWhuWU5Qb2l0SS1BTDc3czhCWjBpMWdsaWxGNUJWbw?oc=5", "source_name": "Investing.com", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Analysts Are Bullish on These Healthcare Stocks: Prime Medicine, Inc. (PRME), Ocular Therapeutix (OCUL)", "summary": "LifeSci Capital analyst Cory Jubinville maintained a Buy rating on Prime Medicine, Inc. (PRME) with a $6.00 price target. Needham analyst Serge Belanger also maintained a Buy rating on Ocular Therapeutix (OCUL) with an $18.00 price target, aligning with a Strong Buy consensus for", "url": "https://www.theglobeandmail.com/investing/markets/stocks/OCUL/pressreleases/2559926/analysts-are-bullish-on-these-healthcare-stocks-prime-medicine-inc-prme-ocular-therapeutix-ocul/", "source_name": "The Globe and Mail", "published_at": "2026-06-20T00:09:09", "published_display": "20 Jun 2026 00:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology Stock Rises 19% in 3 Months: Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxQM0ExNm9zZVBVMzB2cTFsYkhQeDJyeUV5Y1lSdWdsa2V2STFTSFBkYVlrRDJaUmE0bjZVLUxmZEh1UkFPbndtdWVDWmJBcEJaSmpTSlN4RkFkdF9EYkhFUXh3YWxqREkxRllfRXE0bFVuSkMwaExFNmk0UmNoa2R2NmQyb0p1N2pudENMMGMwWmVGT0J5SUxfeE5hT2hpUms1NHR4NzY1VWpNQVFYUWJkUnN3?oc=5", "source_name": "TradingView", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "We're Keeping An Eye On Prime Medicine's (NASDAQ:PRME) Cash Burn Rate", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxNMWRXUTNpcHZJVnN4OXlvaXlOUGplVTRuRUFfdGppaXp4ZUk4LUZhMVRfMnFnbGtlbm02QWw4TDFqLVlTX0xPa3ZFUnpoTEstTUVtUU04NE5ZYWNwVjdkTUR3WldyUDk0dlk5eVRlSHdvT09LZ2Uta3V1X3hyTF90RTBXbElqV0JZUHdrTnpJeUc4MGdoM2Q4ZmtPak9mZw?oc=5", "source_name": "Market source", "published_at": "2026-06-04T07:00:00+00:00", "published_display": "04 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UNH stock jumps on Q1 earnings beat and raised guidance to $18.25+", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxPTEprdzNMNGZxdkg5Wll5MTlvS1dheXQybm14TERTcGVzcHQzY0llOEpTa0dpZ1hGdHVyNWZ2cFFiWmZRdkl1aUp4YVlTMVJxSDRzaEdzRFB1cW93QzdhSmNxcEZDMWhGX2F0ODJFcjY1Mk1kMVhLNnVJSUhVMHZpRjRtTHo2cXBvbVJ3a05SWlJNMUdrSzFPbA?oc=5", "source_name": "eciks.org", "published_at": "2026-05-26T07:00:00+00:00", "published_display": "26 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 84, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Prime Medicine (PRME) Reports Q1 EPS", "summary": "", "url": "https://news.google.com/rss/articles/CBMiggFBVV95cUxQZnBPRUh0ZXc3U3p6RzZ2SmpqM2xLZC1BY3o3cTd4N3BLcEQ3OTl4QkJRTVhZaml2OXdyd2tRMkRGY3FERTRVYjktUFdLZUtueUQySmI4NU9GOUpVWGllMXJxQV93VE1FMDBreVNDTnpOLVlETEc2MXhBLUJoZWJMQzl3?oc=5", "source_name": "Market source", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PDS BIOTECHNOLOGY ($PDSB) Releases Q1 2026 Earnings | PDSB Stock News", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxOcEdqLWM1SmVuNHpvZ2poNU5mOFppaWNtUi1IQVRHTmgxLUpyZHdUSDRnekdzMmVFQzFzUGo2RjlYenpCaTlfcUZhMm1yTzRwWUxnM01WY0libmxIVXNSM3RtMGxMY2RURTdMVW96bGU0SGZXRkE2SnVQdVNNUWw5RWtJQVJMX2pQQnRBRHBKMlRCUDct?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Prime Medicine (Nasdaq: PRME) Q1 2026 results, cash runway into 2027 and pipeline update", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxQd1RCY25tNUFfdkF3SU1mMVlMamMtTkxVQmFPME82S2J1V2hrczZUYXVDSGQ0ZGdPdXpnQWtDVFFYZkxBMU1tRWt5cDdlbjFVaWx1WlZLcjdZWkxUUk5YdEs0YW9SUlN6Qnp1cU1mUHZ0elRhWGxRVEc2VU13TjhzRW41NGRQY0NKVkRPdzZaWDE1eEJudEZzVFZGLXNWOFVIVjNNS2JBcGw3UTQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GE HealthCare (NASDAQ:GEHC) Posts Better-Than-Expected Sales In Q1 CY2026 But Stock Drops", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3gFBVV95cUxOUjRRb0hlcHlOazlmelFaVVJSQWNnRmExZVBEQW1HMmVLTjNyU3d4WElsU05hdGlfYWFSY0twMTNWOVVCY0h4U2dYQ19BQl9pa3o0NWNBLW50WmFsSEVHdmJFV3JabnN5MFZpUWZabjZzY2tjMUtxbndONm9DS3NxTUp3Qjg2dWZnMDR2NXZ2eU80MWhSODVKdVgxZVJ6TWs3RFpCaDFqMXVtVkhmRVlOcWtqYUV1X1FPcGpfdERhRmwzdkZDaWxtSnJnd25Oam4yTnFHTFBkZi0tM1BZdkE?oc=5", "source_name": "StockStory", "published_at": "2026-04-29T07:00:00+00:00", "published_display": "29 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Abbott is the most oversold healthcare stock as Q1 earnings roll on (XLV:NYSEARCA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxOc2thQjFpazgwaFRfS3NjVXhlTkdFWHNFb240S0Z6akFtQXFIMmFmaXZnQ1A3OFVCQW9DT25OLVBQdGN5Yk52Mk9yUFlSX19ZS3FRTjZoR05zc2FVc25pVHQ0TDVHT2JmVnJabGNCREdLT2stV0IzLVdHWXpFZGU3V1NnVGhYbFRzNURVek41TVRmLWZQZTFYUkc4aXM0a1cwTkNFYTBfVnQ?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-04-22T07:00:00+00:00", "published_display": "22 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CFO package at Prime Medicine (NASDAQ: PRME) details pay, options and severance", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxPb1hTSVozUW1hQVZQeElHUHBCR2tnTXNpUkZVSEdQZFNudmRCd0VJX2NUUHhSZU9tN2dFaUhiWXJzOXVwYkk2RDhFb1R0SWdrSWhrb2VVbWpmbXNOaF9jbng1OWhqVFNJTVdKd2hSRTRkSWNjTXRDS0lRQl9LZ21mSy1WZzdmMGtzdVF5MFZmMEFwYW9FeDI3M0RtSnNBRWNnTWVick5VOWsxZjg?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-16T07:00:00+00:00", "published_display": "16 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxQcjZqdzdBcURDdWxCZUtoU1dTaHYtVUFRdlo1a3ZGZGY3a1dBX2x2UVE3Y1hoX1duLXhGU2p0UXU2eTctNng5eFJ5c1M0bHBNQ0VmZTFZanhYU21yTVo0UTQtVENveVV1aWdpc3luUlgza3AyUEI2OGx4aEhXc0pBTHpWUThSYXI1S3RTS21lQ21vWjd6MGY4ZDRwVWlEakc3SmFKN09aM0Rlb2pFT3BNNW1GTExnSElFb2NqR3JhX0J3MlptQy1mMk9IOTZtdS1HU25fLU9aOU9XZi1PRDlkZVI2cnhackHSAewBQVVfeXFMTlc2N3pIUkxDd1NtTlVRMEdac1JNSDF3cUNidkZrTElQREZaUTZjZmFHdUVWYW8wcDg1LThGbnlPb0VQUFI4ZXdjSXR6Ym5DREM1X2lyQUtYTzF3XzBBTGRGcEZQQ3FjLWxCQ0locVM2dGZJR1kxYmlBQXdsbFhfbFFISS1wSUkxQmp4U2d2Z3JHbXRPMUpnajBydTRmNnQzZmF5eEdzOVFRNUdDNVV0aDJQNERCaXN3ZGo1UUc1ZGkwOFYzcDgxS1ltZllDeTFxNFIxT3FyOUxLMFNrLUhtOFNFV0xMYkM5TlpWMzk?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 100, "total_relevant": 75, "sentiment_summary": {"positive": 26, "negative": 7, "neutral": 42, "score": 58, "total": 75, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 78, "events": [{"event": "general", "label": "Market update", "weight": 21.6, "count": 38}, {"event": "earnings", "label": "Earnings", "weight": 11.29, "count": 21}, {"event": "analyst", "label": "Analyst action", "weight": 3.85, "count": 7}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 3.3, "count": 6}, {"event": "liquidity", "label": "Balance sheet", "weight": 1.1, "count": 2}, {"event": "guidance", "label": "Guidance", "weight": 0.55, "count": 1}], "positive_events": 26, "negative_events": 7}, "market_context": {"has_market_context": true, "latest_close": 3.78, "latest_week": "2026-07-10", "one_week_move": -2.3, "four_week_move": 36.2, "twelve_week_move": -0.8, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": 0.556729, "market_dynamics_buy_signal": false, "relative_strength": -16.832535, "fair_value_gap": -24.4, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "negative", "expectation_probability": 44.2211, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-2.3% over one week, +36.2% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 67, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 7}, {"label": "Investing.com", "count": 6}, {"label": "TradingView", "count": 5}, {"label": "Moomoo", "count": 5}, {"label": "Stock Titan", "count": 4}, {"label": "MarketBeat", "count": 3}, {"label": "Insider Monkey", "count": 2}, {"label": "timothysykes.com", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 68}, {"label": "Industry context", "count": 7}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 38}, {"label": "Earnings", "count": 21}, {"label": "Analyst action", "count": 7}, {"label": "Regulatory and legal", "count": 6}, {"label": "Balance sheet", "count": 2}, {"label": "Guidance", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "58/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "78/100 classification confidence."}, {"label": "Company focus", "value": "68", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "4", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-2.3% over one week, +36.2% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "Prime Medicine (PRME) Reaches Positive Resolution to Arbitration with Beam Therapeutics"}], "updated_at": "2026-07-16T11:52:28.651695+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}